Positive study data could improve standard of care for Hodgkin lymphoma patients

In a late-stage clinical trial, Hodgkin lymphoma patients who received brentuximab vedotin post-transplant lived longer without disease progression than patients who received only supportive care. —> Read More Here


Leave a Reply

Your email address will not be published. Required fields are marked *